慢性乙型肝炎相关性肝细胞癌的危险因素研究进展

肝脏 ›› 2023, Vol. 28 ›› Issue (1): 124-127.

慢性乙型肝炎相关性肝细胞癌的危险因素研究进展

黄燕萍, 张琴, 孙明瑜

201203 上海中医药大学(黄燕萍,孙明瑜);上海交通大学医学院附属同仁医院(黄燕萍,张琴);上海中医药大学附属曙光医院,上海中医药大学肝病研究所,肝肾疾病病症教育部重点实验室(孙明瑜)

收稿日期:2022-07-25 出版日期:2023-01-31 发布日期:2023-02-21
通讯作者: 孙明瑜,Email:mysun369@126.com
基金资助:
上海市科委“科技创新行动计划”项目(19401972300);山东省重点研发计划“重大科技创新工程”(2021CXGC010509);国家中医药管理局第四批中医优才(2017-124);国家中医药管理局慢性肝病虚损重点研究室和上海市中医临床重点实验室(20DZ2272200)等资助

Received:2022-07-25 Online:2023-01-31 Published:2023-02-21

摘要/Abstract

摘要： 慢性乙型病毒性肝炎是我国肝癌的最主要病因,肝癌的早筛早治有利于改善患者的预后。目前还没有可以直接诊断的早期标志物,因此对慢性乙型肝炎患者发生肝细胞癌的危险因素研究,具有重要意义。本篇综述主要总结了慢性乙型肝炎进展至肝癌的危险因素。慢乙肝患者在HBsAg阴转后仍需监测肝癌的发生。

黄燕萍, 张琴, 孙明瑜. 慢性乙型肝炎相关性肝细胞癌的危险因素研究进展[J]. 肝脏, 2023, 28(1): 124-127.

[1] WHO. Global Hepatitis Report, 2017. Geneva: World Health Organization, 2017.
[2] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol,2018,3(6):383-403.
[3] Liu J, Zhang SK, Wang QM, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study. Lancet Infect Dis. 2016,16(1):80-86.
[4] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021,71(3):209-249.
[5] Chen WQ, ZhengRS, Baade PD, et al. Cancer statistis in China,2015. CA Cancer J Clin. 2016,66(2):115-132.
[6] Allemani C, Matsuda T, Carlo VD, et al. Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet,2018,17;391(10125):1023-1075.
[7] Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health, 2020,8(2):e180-e190.
[8] Jang JW, Kin JS, Kim HS, et al. Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Clin mol hepatol,2021,27(1):207-218.
[9] Lee. Old hepatitis B virus never dies: It just hides itself within the host genome. Clin Mol Hepatol,2021,27(1):107-109.
[10] 郑传芬,曾惠,王佳,等. 重庆地区黄曲霉毒素暴露与原发性肝癌关联的病例对照研究. 中华预防医学杂志,2017,51(6):539-545.
[11] Zhang WL, He H,Zang MY,et al. Genetic features of aflatoxin associated hepatocellular carcinoma. Gastroenterology,2017,153(1):249-262.e2.
[12] Mak LY, Cruz-Ramon V, Chinchilla-Lopez P, et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book. 2018,May 23;38:262-279.
[13] Liu X, Baecker A, Wu M, et al. Interaction between tobacco smoking and hepatitis B virus infection on the risk of liver cancer in a Chinese population. Int J Cancer,2018,142(8):1560-1567.
[14] Chuang SC,Lee YCA,Wu GJ,et al. Alcohol consumption and liver cancer risk:a meta analysis. Cancer Causes Control,2015,26(9):1205-1231.
[15] Pang YJ, Kartsonaki C, Turnbull L, et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: a prospective study of 0.5 million people. Hepatology,2018,68(4):1308-1318.
[16] Sohn W, Lee HW, Lee S, et al. Obesity and the risk of primary liver cancer: a systematic review and meta-analysis. Clin Mol Hepatol,2021,27(1):157-174.
[17] Yu MW, Lin CL, Liu CJ, et al. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B:a large cohort study. Gastroenterology.2017,153(4):1006-1017.e5.
[18] Ma X,Yang Y, Li HL,et al. Dietary trace element intake and liver cancer risk: Results from two population- based cohorts in China. Int J Cancer,2017,140(5):1050-1059.
[19] Lok ASF, Mcmahon BJ, Brown RS, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology,2016,63(1):284-306.
[20] Yip TC, Wong GL, Chan HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol, 2019,70(3):361-370.
[21] Kim JH, Sinn DH,Kang W,et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology,2017,66(2):335-343.
[22] Kim GAK, Lim YS, Han SB, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut,2018,67(5):945-952.
[23] Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol Int,2017,11(4):317-370.
[24] 贾蓉蓉,霍荣瑞,骆成飘,等.乙型肝炎表面抗原转阴患者发生肝细胞癌危险因素的系统评价. 中国循证医学杂志,2018,18(12):1311-1317.
[25] Kuang XJ, Jia RR, Huo RR,et al. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Viral Hepat,2018,25(9)1026-1027.
[26] Dave S,Park S, Murad MH,et al.Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis. Hepatology,2021,73(1):68-78.
[27] Yip TCF, Wong VWS, Chan HLY, et al. Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China. Gastroenterology,2020,158(1):215-225.e6.
[28] Chang TS, Yang YH, Chen WM, et al. Long term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B. Sci Rep,2021,11(1):1365.
[29] Liang KH, Hsu CW, Chang ML, et al. Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis,2016,213(6):966-974.
[30] Ren PP, Cao ZJ, Mo RD, et al.Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther,2018,18(10):1085-1094.
[31] Li XK, Zhou DQ, Chi XL, et al. Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial. Hepatol Int,2020,14(6):985-996.
[32] Xing YF, Wei CS,Zhou TR, et al. Efficacy of a Chinese herbal formula on hepatitis B e antigenpositivechronic hepatitis B patients. World J Gastroenterol,2020,26(30):4501-4522.

慢性乙型肝炎相关性肝细胞癌的危险因素研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	何青莲, 余保平, 肖勇. 肝硬化食管胃静脉曲张出血患者内镜治疗后再出血的危险因素分析[J]. 肝脏, 2023, 28(1): 55-60.
[2]	刘民强, 查晓亮, 黄湘荣, 吴强, 何仁亮. 肝癌射频消融患者术后中重度疼痛的危险因素分析[J]. 肝脏, 2022, 27(6): 640-643.
[3]	刘益, 周自忠, 刘刚, 徐海荣. 食管胃底静脉曲张破裂出血患者急诊TIPS术后肝性脑病发生特征及危险因素分析[J]. 肝脏, 2022, 27(6): 658-661.
[4]	冯丹妮, 张达利, 贺希, 张利娟, 周双男, 高银杰, 刘鸿凌. 酒精性肝硬化的肝移植受者血小板减少的病例对照研究[J]. 肝脏, 2022, 27(5): 540-542.
[5]	陈之强, 杨琦, 彭正, 陈艳军. 外伤性肝破裂患者腹腔镜下修补术后并发症的危险因素研究[J]. 肝脏, 2022, 27(5): 580-583.
[6]	柳涛, 刘雅丽, 肖鹏, 高沿航. 遗传变异对酒精性肝病的影响[J]. 肝脏, 2022, 27(4): 389-390.
[7]	车莹, 黄晓铨, 陈世耀. 用循证观点看待肝硬化门静脉血栓诊治中的争议[J]. 肝脏, 2022, 27(3): 261-263.
[8]	楼建军, 张芳芳, 黄妍, 桑玉尔. 营养风险与肝硬化食管胃底静脉曲张内镜治疗术后感染增加相关[J]. 肝脏, 2022, 27(11): 1183-1188.
[9]	陈姣艳, 陈斌, 曹冬容, 朱蔓然, 焦志勇, 秦永军, 夏悯馨. 慢性乙型肝炎并发肝衰竭死亡危险因素的研究[J]. 肝脏, 2021, 26(9): 994-997.
[10]	周静, 刘玉姣, 高园, 谷昊. 肝脏切除术后患者发生谵妄危险因素的meta分析[J]. 肝脏, 2021, 26(9): 1031-1035.
[11]	范文瀚, 梁雪松, 陈怡, 廖威, 李成忠. 免疫抑制剂治疗过程中HBV再激活人群危险因素分析[J]. 肝脏, 2021, 26(8): 843-846.
[12]	杨庆玺, 苏吉亮, 孙忠文, 刘元勋, 胡文娟. 21例肝癌合并脑梗死患者临床特点观察[J]. 肝脏, 2021, 26(6): 642-645.
[13]	商连琴, 岳冬黎, 朱炳喜. 乙型肝炎肝硬化上消化道出血无创性预测模型的建立[J]. 肝脏, 2021, 26(5): 497-501.
[14]	季媛媛, 陈艳清, 程琳, 周海东. 凝血酶原时间是慢性乙型肝炎患者肝活检纤维化程度的独立危险因素[J]. 肝脏, 2021, 26(4): 400-402.
[15]	杜静园, 颜华东. 不同病因肝硬化失代偿患者临床特征及长期预后危险因素的前瞻性队列研究[J]. 肝脏, 2021, 26(2): 140-146.